Mode
Home
Research
Clinical Trials Drug Pipeline Weekly Digests
Reference
Conditions Medications
Community
Questions
Text Size
Log in / Sign up
Home › Medications › omalizumab

omalizumab

7 published articles · Updated continuously

Clinical Trial Landscape

Clinical Trials of omalizumab

62 trials tracked of omalizumab: 40 in phase 3 or 4 and 17 with published results. The most-cited published study has 310 citations.

62Trials tracked
40Phase 3 & 4
0Recruiting
17With published results
Phase distribution
Phase 4 21 Phase 3 19 Phase 2 20 Phase 1 1 Other / NA 1
  1. Phase 3 Omalizumab as Monotherapy and as Adjunct Therapy to Multi-Allergen OIT in Food Allergic Participants Completed · 310 cited
  2. Phase 3 Impact of Omalizumab on Quality of Life Measures and Angioedema Occurrence in Patients With CSU Refractory to Therapy Completed · 128 cited
  3. Phase 3 A Clinical Trial of Omalizumab in Participants With Chronic Rhinosinusitis With Nasal Polyps Completed · 98 cited
  4. Phase 3 A Clinical Trial of Omalizumab in Participants With Chronic Rhinosinusitus With Nasal Polyps Completed · 97 cited
  5. Phase 3 A Phase III Study of and Efficacy of Ligelizumab in the Treatment of CSU in Adolescents and Adults Inadequately Controlled With H1-antihistamines. Completed · 66 cited
  6. Phase 3 A Phase III Study of Safety and Efficacy of Ligelizumab in the Treatment of CSU in Adolescents and Adults Inadequately Controlled With H1-antihistamines Completed · 65 cited
Show 44 more trials
  1. Phase 4 Therapeutic Utility of Xolair in Patients Undergoing Aspirin Desensitization Completed · 63 cited
  2. Phase 3 OPTIMA: Efficacy of Optimized Re-treatment and Step-up Therapy With Omalizumab in Chronic Spontaneous Urticaria (CSU) Patients Completed · 38 cited
  3. Phase 4 Role of Immunoglobulin E (IgE) Bearing Cells in Chronic Idiopathic Urticaria (CIU) Completed · 36 cited
  4. Phase 4 Omalizumab to Mepolizumab Switch Study in Severe Eosinophilic Asthma Patients Completed · 35 cited
  5. Phase 4 EValuating trEatment RESponses of Dupilumab Versus Omalizumab in Type 2 Patients Completed · 35 cited
  6. Phase 3 Study of Efficacy and Safety of Xolair® (Omalizumab) in Chinese Patients With Chronic Spontaneous Urticaria Completed · 29 cited
  7. Phase 4 A Study of the Efficacy and Safety of Omalizumab Through 48 Weeks in Participants With Chronic Idiopathic Urticaria Completed · 21 cited
  8. Phase 3 An Extension Study of Omalizumab in Participants With Chronic Rhinosinusitis With Nasal Polyps Completed · 21 cited
  9. Phase 4 A Study in Participants With Asthma Initiating Treatment With Omalizumab (Xolair) Completed · 20 cited
  10. Phase 4 Treatment of Idiopathic Angioedema With Xolair as Add-on Therapy Completed · 15 cited
  11. Phase 4 Effect of Omalizumab (Xolair) on Basophils in Patients With Chronic Idiopathic Urticaria Completed · 4 cited
  12. Phase 4 Predicting the Clinical Response to Omalizumab With Anti-Immunoglobulin E (IgE) Ab Response or Syk Expression in Basophils Completed
  13. Phase 4 Omalizumab in Chronic Spontaneous Urticaria Patients Non Responding to Initial Standard antihistaminE Treatment Completed
  14. Phase 4 Immunologic Basis of Anti-IgE Therapy (Study II: On Patients With Asthma) Completed
  15. Phase 4 Effect of Omalizumab on Expression of IgE Receptors in Adults With Severe, Inadequately Controlled Allergic Asthma Completed
  16. Phase 4 Efficacy and Safety of Omalizumab in Bullous Pemphigoid Completed
  17. Phase 4 A Study of Omalizumab in Preventing Bronchoconstriction Following Environmental Cat Dander Exposure in Patients With Cat Dander-induced Asthma Completed
  18. Phase 4 A Study Evaluating the Persistency of Response With or Without Xolair (Omalizumab) After Long-term Therapy Completed
  19. Phase 4 Preventative Omalizumab or Step-up Therapy for Severe Fall Exacerbations Completed
  20. Phase 4 Omalizumab Use and Asthma-Related Quality of Life in Patients With Severe Persistent Allergic Asthma Completed
  21. Phase 4 Evaluate the Effect of Omalizumab on Markers of Asthma Impairment in Patients With Persistent Allergic Asthma Completed
  22. Phase 4 Inner-City Anti-IgE Therapy for Asthma Completed
  23. Phase 4 Study to Evaluate the Effect of Omalizumab on Improving the Tolerability of Specific Immunotherapy in Patients With Persistent Allergic Asthma Completed
  24. Phase 4 Omalizumab in Adult and Adolescent Patients With Severe Persistent Allergic Asthma Completed
  25. Phase 3 Study of Efficacy and Safety of Omalizumab in Refractory Chronic Spontaneous Urticaria Patients Completed
  26. Phase 3 Study of Efficacy and Safety of Omalizumab in Severe Japanese Cedar Pollinosis Adult and Adolescent Patients Completed
  27. Phase 3 A Study to Evaluate the Efficacy, Response Duration and Safety of Xolair (Omalizumab) in Patients With Chronic Idiopathic Urticaria (CIU)/Chronic Spontaneous Urticaria (CSU) Who Remain Symptomatic Despite Antihistamine Treatment (H1) Completed
  28. Phase 3 A Study of the Efficacy and Safety of Omalizumab (Xolair) in Patients With Chronic Idiopathic Urticaria (CIU)/Chronic Spontaneous Urticaria (CSU) Who Remain Symptomatic Despite Antihistamine (H1) Treatment Completed
  29. Phase 3 Effect of Omalizumab in Patients With Severe Persistent Non-atopic Uncontrolled Asthma Completed
  30. Phase 3 Open Label Study to Assess Safety and Immunogenicity of Omalizumab Liquid Formulation. Completed
  31. Phase 3 Omalizumab in Patients With Moderate to Severe Persistent Allergic Asthma Not Adequately Controlled Despite GINA (2009) Step 4 Therapy Completed
  32. Phase 3 Efficacy/ Safety of Omalizumab in Patients With Seasonal Allergic Asthma and Seasonal Allergic Rhinoconjunctivitis Completed
  33. Phase 3 A Safety Study of Xolair (Omalizumab) in Patients With Chronic Idiopathic Urticaria (CIU) Who Remain Symptomatic Despite Treatment With H1 Antihistamines, H2 Blockers, and/or Leukotriene Receptor Antagonists Completed
  34. Phase 3 Efficacy and Safety of Omalizumab in Children (6 - < 12 Years) With Moderate-severe, Inadequately Controlled Allergic Asthma Completed
  35. Phase 2 Study to Evaluate Tezepelumab in Adults With Chronic Spontaneous Urticaria Completed
  36. Phase 2 The Effects of Omalizumab (Anti-IgE) on the Late-phase Response to Nasal Allergen Challenge Completed
  37. Phase 2 Peanut Oral Immunotherapy and Anti-Immunoglobulin E (IgE) for Peanut Allergy Completed
  38. Phase 2 Multi OIT to Test Immune Markers After Minimum Maintenance Dose Completed
  39. Phase 2 Peanut Reactivity Reduced by Oral Tolerance in an Anti-IgE Clinical Trial Completed
  40. Phase 2 Cold Urticaria Treatment With Xolair Completed
  41. Phase 2 Omalizumab in the Treatment of Peanut Allergy Completed
  42. Phase 2 Multi Immunotherapy to Test Tolerance and Xolair Completed
  43. Phase 2 A Pilot Study of the Treatment of Eosinophilic Esophagitis With Omalizumab Completed
  44. Phase 2 A Study of Xolair (Omalizumab) in Patients With Chronic Idiopathic Urticaria (CIU) Who Remain Symptomatic With Antihistamine Treatment (H1) Completed

Showing the 50 most-cited and recently-updated of 62 trials. Browse the full registry →

Trial data sourced from ClinicalTrials.gov. Counts describe the research landscape and are not a treatment recommendation. Informational only — not medical advice.

HCP Mode — summaries include clinical detail, trial data, and statistical outcomes.
Patient Mode — summaries use plain language, avoiding clinical jargon.
Therapeutic advances in IgE-mediated food allergy lack validated risk-stratification tools for individualized care
Allergy & Immunology Sys. Review
Therapeutic advances in IgE-mediated food allergy lack validated risk-stratification tools for individualized care Newer treatments for food allergies lack clear safety tools
This mini review synthesizes therapeutic innovations for IgE-mediated food allergy, including oral immunotherapy, omalizumab, and combinatio…
Doctors are looking for better ways to manage food allergies, but they currently lack validated tools to help decide which specific treatmen…
Frontiers Jul 2, 2026
Biologic-assisted immunotherapy including omalizumab and dupilumab may support oral and sublingual immunotherapy for pediatric food allergies
Allergy & Immunology Meta-analysis
Biologic-assisted immunotherapy including omalizumab and dupilumab may support oral and sublingual immunotherapy for pediatric food allergies New review explores biologic drugs for food allergy in children
This systematic review examines the efficacy, safety, and clinical applicability of biologic-assisted immunotherapies, such as omalizumab an…
A systematic review looks at whether adding biologic drugs like omalizumab to immunotherapy helps kids with food allergies.
Frontiers Jun 22, 2026
Omalizumab may improve asthma and food allergy in a pediatric liver transplant recipient
Pediatrics Sys. Review
Omalizumab may improve asthma and food allergy in a pediatric liver transplant recipient Omalizumab helps teen with food allergy after liver transplant
A narrative review of a case report describes a 15-year-old boy with a liver transplant and de novo post-transplant food allergy who receive…
A 15-year-old with a liver transplant and severe food allergies improved with omalizumab, gaining asthma control and a less restricted diet.
Frontiers Jun 17, 2026
Switching Biologics in Severe Asthma Patients Shows Improved Clinical Outcomes and Reduced Exacerbations Across Multiple Therapies
Allergy & Immunology Meta-analysis
Switching Biologics in Severe Asthma Patients Shows Improved Clinical Outcomes and Reduced Exacerbations Across Multiple Therapies Switching Asthma Drugs Could Change Your Life
A systematic review and meta-analysis of 2,292 patients found that switching biologics significantly reduced exacerbations and improved asth…
If your severe asthma medication stops working, switching to a different biologic drug could cut your attacks in half and help you breathe e…
May 5, 2026
Narrative review highlights mechanistic gaps and limited efficacy in chronic inducible urticaria treatment options
Allergy & Immunology Sys. Review
Narrative review highlights mechanistic gaps and limited efficacy in chronic inducible urticaria treatment options New Hope for Chronic Hives Targets Specific Triggers
This narrative review examines chronic inducible urticaria (CIndU), focusing on H1-antihistamines, omalizumab, anti-KIT biologics, and BTK i…
New medicines are being built to fix the exact reason your hives appear, moving away from a one-size-fits-all approach.
Frontiers Apr 24, 2026
Retrospective case series evaluates omalizumab efficacy in Chinese pediatric chronic spontaneous urticaria patients
Pediatrics Cohort
Retrospective case series evaluates omalizumab efficacy in Chinese pediatric chronic spontaneous urticaria patients This Hives Medicine Might Help Young Children Finally Find Relief
This retrospective case series assessed omalizumab in 13 Chinese children under 12 years with chronic spontaneous urticaria.
A common hives drug shows promise for younger kids who usually have few options.
Frontiers Apr 21, 2026
Machine learning model predicts omalizumab efficacy duration in moderate-to-severe perennial allergic rhinitis patients
Allergy & Immunology Cohort
Machine learning model predicts omalizumab efficacy duration in moderate-to-severe perennial allergic rhinitis patients A smart model that predicts how long your allergy shot will last
This retrospective cohort study evaluated predictors of omalizumab efficacy duration in 561 patients with moderate-to-severe perennial aller…
A new computer model can estimate how long a popular allergy shot will keep working for each person, making treatment more personal.
Frontiers Apr 13, 2026